New painkiller may cut opioid use after breast reduction
NCT ID NCT05891613
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This study tested two different painkillers for women undergoing breast reduction surgery. One is a long-acting version called liposomal bupivacaine (Exparel), and the other is standard bupivacaine. Researchers measured pain scores and how much opioid pain medicine was needed in the first three days after surgery. The goal is to find a better way to manage pain and reduce reliance on opioids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST REDUCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Liposomal bupivacaine (Exparel) and bupivacaine hydrochloride
What this could lead to
If it works, this could point toward a better way to manage pain after breast reduction, possibly reducing the need for opioids.
What could go wrong
This is a small, single-blind, non-randomized trial with only 32 participants, so results may not apply to everyone. The two drugs are compared on different breasts in the same person, which may not reflect real-world use.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.